Bloomberg Law
Nov. 15, 2022, 8:05 PM

AstraZeneca, Sanofi, Novo Nordisk Battle HHS on Drug Discounts

Ian Lopez
Ian Lopez
Senior Reporter

A trio of major drugmakers sparred with the Health and Human Services Department on Tuesday over obligations for providing cheap drugs under a federal program meant to service low-income Americans’ medical needs.

Attorneys for Novo Nordisk, Sanofi and AstraZeneca went before a three judge panel at the US Court of Appeals for the Third Circuit to dispute whether the government’s 340B program requires the companies to offer steeply discounted drugs through for-profit pharmacies that operate in contract with health-care providers participating in the program.

The battles hinge on whether the HHS or drugmakers have the final call on how many, ...

Learn more about Bloomberg Law or Log In to keep reading:

Learn About Bloomberg Law

AI-powered legal analytics, workflow tools and premium legal & business news.

Already a subscriber?

Log in to keep reading or access research tools.